Pretreatment of Human Platelets with Plasmin Inhibits Responses toThrombin, but Potentiates Responses to Low Concentrations of Aggregating Agents, Including the Thrombin Receptor Activating Peptide, SFLLRN

R L Kinlough-Rathbone; D W Perry; M L Rand; M A Packham

doi:10.1055/s-0038-1656044

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1997; 77(04): 741-747
DOI: 10.1055/s-0038-1656044

Platelets

Schattauer GmbH Stuttgart

Pretreatment of Human Platelets with Plasmin Inhibits Responses toThrombin, but Potentiates Responses to Low Concentrations of Aggregating Agents, Including the Thrombin Receptor Activating Peptide, SFLLRN

R L Kinlough-Rathbone

¹The Department of Pathology, McMaster University, Hamilton, Ontario, Canada

,

D W Perry

¹The Department of Pathology, McMaster University, Hamilton, Ontario, Canada

,

M L Rand

²The Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada

,

M A Packham

²The Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Effects of plasmin on platelets, that influence subsequent responses to aggregating agents, are relevant to attempts to prevent rethrombosis following administration of fibrinolytic agents. We describe plasmin-induced inhibition of platelet responses to thrombin, but potentiation of responses to other aggregating agents. Washed human platelets were labeled with ¹⁴C-serotonin, treated for 30 min at 37° C with 0, 0.1 or 0.2 CU/ml of plasmin, followed by aprotinin, washed and resuspended in a Tyrode-albumin solution with apyrase. Incubation with 0.2 CU/ml of plasmin almost completely inhibited thrombin-induced (0.1 U/ml) aggregation, release of ¹⁴C-serotonin, and increase in cytosolic [Ca²⁺]. In contrast, with plasmin-pretreated platelets, aggregation and release of ¹⁴C-serotonin were strongly potentiated in response to low concentrations of the thrombin receptor-activating peptide SFLLRN, ADP, platelet-activating factor, collagen, arachidonic acid, the thromboxane mimetic U46619, and the calcium ionophores A23187 and ionomycin. Aspirin or RGDS partially inhibited potentiation. Plasmin-pretreated platelets resuspended in plasma anticoagulated with FPRCH₂C1 (PPACK) also showed enhanced responses to aggregating agents other than thrombin. The contrasting effects on responses to thrombin and SFLLRN are noteworthy. Plasmin cleaves GPIIb/IIIa so that it becomes a competent fibrinogen receptor, and binding of ¹²⁵I-fibrinogen during ADP-induced aggregation was greatly potentiated within 10 s. Potentiation of aggregation by other agonists may be due to increased binding of released fibrinogen. Thus, platelets freed from a thrombus may have increased responsiveness to low concentrations of aggregating agents other than thrombin. These results provide further support for the use of inhibitors of platelet reactions in conjunction with administration of fibrinolytic agents.

PDF (2261 kb)

Referenzen

References
1 Gaffney PJ, Longstaff C. An overview of fibrinolysis. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. 3rd. Churchill Livingstone; Edinburgh. 1994. pp 549-573
2 Runge MS, Haber E. Thrombosis and thrombolysis in cardiovascular diseases: an overview. In: The Heart and Cardiovascular System. Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. eds. 2nd. Raven Press; New York: 1992. pp 207-217
3 Greenberg JP, Packham MA, Guccione MA, Rand ML, Reimers H-J, Mustard JF. Survival of rabbit platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood 1979; 53: 916-927
4 Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein IB-von Willebrand factor interactions. Blood 1985; 65: 32-40
5 Michelson AD, Barnard MR. Plasmin-induced redistribution of platelet glycoprotein lb. Blood 1990; 76: 2005-2010
6 Beer J, Coller BS. Evidence that platelet glycoprotein Ilia has a large disulfide-bonded loop that is susceptible to proteolytic cleavage. J Biol Chem 1989; 264: 17564-17573
7 Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IMIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404-414
8 Rabhi-Sabile S, Pidard D. Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors. Thromb Haemost 1995; 73: 693-701
9 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
10 Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: The Heart and Cardiovascular System. Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. eds. 02. nd Raven Press; New York: 1992. pp 219-273
11 Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J Clin Invest 1973; 52: 1647-1659
12 Schafer AI, Maas AK, Ware JA, Johnson PC, Rittenhouse SE, Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986; 78: 73-79
13 Guccione MA, Kinlough-Rathbone RL, Packham MA, Harfenist EJ, Rand ML, Greenberg JP, Perry DW, Mustard JF. Effects of plasmin on rabbit platelets. Thromb Haemost 1985; 53: 08-14
14 Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 1992; 79: 91-98
15 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
16 Coughlin SR. Thrombin receptor structure and function. Thromb Haemost 1993; 70: 184-187
17 Vouret-Craviari V, Grail D, Chambard J-C, Rasmussen UB, Pouysségur J, Van Obberghen-Schilling E. Post-translational and activation-dependent modifications of the G protein-coupled thrombin receptor. J Biol Chem 1995; 270: 8367-8372
18 Miller JL, Katz AJ, Feinstein MB. Plasmin inhibition of thrombin-induced platelet aggregation. Thromb Diath Haemorrh 1975; 33: 286-309
19 Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75: 456-461
20 Lu BH, Soria C, Cramer EM, Soria J, Maclouf J, Perrot JY, Li H, Commin PL, Schumann F, Regnier O, Lijnen RH, Caen JP. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood 1991; 77: 996-1005
21 Dittmar S, Gear ARL. The influence of recombinant tissue-type plasminogen activator and plasmin on platelet aggregation: a quenched-flow study. Fibrinolysis 1993; 7: 158-164
22 Kowalski E, Kopec M, Wegrzynowicz Z. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thromb Diath Haemorrh 1964; 10: 406-423
23 Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet-rich plasma. Fibrinolysis 1993; 07: 379-385
24 Lebrazi J, Abdelouahed M, Mirshahi M, Samama MM, Lecompte T. Streptokinase and APSAC inhibit platelet aggregation in vitro by fibrinogenoly-sis: effect of plasma fibrinogen degradation products X and E. Fibrinolysis 1995; 09: 113-119
25 Fry ETA, Grace AM, Sobel BE. Interactions between pharmacologic concentrations of plasminogen activators and platelets. Fibrinolysis 1989; 03: 127-136
26 Gouin I, Lecompte T, Morel M-C, Lebrazi J, Modderman PW, Kaplan C, Samama MM. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation 1992; 85: 935-941
27 Cramer EM, Lu H, Caen JP, Soria C, Bemdt MC, Tenza D. Differential redistribution of platelet glycoproteins lb and Ilb-IIIa after plasmin stimulation. Blood 1991; 77: 694-699
28 Lu H, Soria C, Soria J, de RomeufC, Perrot J-Y, Tenza D, Garcia I, Caen JP, Cramer EM. Reversible translocation of glycoprotein lb in plasmin-treated platelets: consequences for platelet function. Eur J Clin Invest 1993; 23: 785-793
29 Greenberg JP, Packham MA, Guccione MA, Harfenist EJ, Orr JL, Kin-lough-Rathbone RL, Perry DW, Mustard JF. The effect of pretreatment of human or rabbit platelets with chymotrypsin on their responses to human fibrinogen and aggregating agents. Blood 1979; 54: 753-765
30 Pidard D, Frelinger AL, Bouillot C, Nurden AT. Activation of the fibrinogen receptor on human platelets exposed to alpha chymotrypsin. Relationship with a major proteolytic cleavage at the carboxyterminus of the membrane glycoprotein lib heavy chain. Eur J Biochem 1991; 200: 437-447
31 Komecki E, Ehrlich YH, de MarsD D, Lenox RH. Exposure of fibrinogen receptors in human platelets by surface proteolysis with elastase. J Clin Invest 1986; 77: 750-756
32 Pidard D, Theodet J-C, Renesto P, Chignard M. The effects of serine pro-teinases on the platelet fibrinogen receptor. Thromb Haemost 1991; 65: 1066
33 Niewiarowski S, Gurewich V, Senyi AF, Mustard JF. The effect of fibrinolysis on platelet function. In: Thrombolytic Therapy. Thromb Diath Haemorrh. 1971. suppl 47. 99-111
34 Kinlough-Rathbone RL, Perry DW, Packham MA. Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of¹⁴C-serotonin by human platelets pretreated with chymotrypsin or Serratia marcescens protease. Thromb Haemost 1995; 73: 122-125
35 Molino M, Blanchard N, Belmonte E, Tarver AP, Abrams C, Hoxie JA, Cerletti C, Brass LF. Proteolysis of the human platelet and endothelial cell thrombin receptor by neutrophil-derived cathepsin G. J Biol Chem 1995; 270: 11168-11175
36 Cazenave J-P, Blondowska D, Richardson M, Kinlough-Rathbone RL, Packham MA, Mustard JF. Quantitative radioisotopic measurement and scanning electron microscopic study of platelet adherence to a collagen-coated surface and to subendothelium with a rotating probe device. J Lab Clin Med 1979; 93: 60-70
37 Molnar J, Lorand L. Studies on apyrases. Arch Biochem Biophys 1961; 93: 353-63
38 Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. In: Methods in Hematology. Measurements of Platelet Function. Harker LA, Zimmerman TS. eds. Churchill Livingstone; Edinburgh. 1983. pp 64-91
39 Tuszynski GP, Knight L, Piperno JR, Walsh PN. A rapid method for removal of [¹²⁵I]iodide following iodination of protein solutions. Analyt Biochem 1980; 106: 118-122
40 Aster RH, Jandl JH. Platelet sequestration in man. I Methods J Clin Invest 1964; 43: 843-855
41 Pollock WK, Rink TJ, Irvine RF. Liberation of [³H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochem J 1986; 235: 869-877
42 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354
43 Whitehead TP, Kricka LJ, Carter TJN, Thorpe GHG. Analytical luminescence: its potential in the clinical laboratory. Clin Chem 1979; 25: 1531-1546
44 Lukasiewicz H, Peng M-L, Morinelli TA, Eckardt A, Kirby EP, Niewiarowski S. Separation of different receptor-mediated effects of a prostaglandin H2 analogue (U46619) on human platelets by means of human granulocytic elastase and chymotrypsin. Biochem Pharmacol 1089; 38: 3213-3217